Literature DB >> 9915902

Fumonisin B1 consumption by rats causes reversible, dose-dependent increases in urinary sphinganine and sphingosine.

E Wang1, R T Riley, F I Meredith, A H Merrill.   

Abstract

Fumonisin B1 (FB1) is a frequently encountered mycotoxin that inhibits ceramide synthase, the enzyme that acylates sphinganine, sphingosine and other "sphingoid" bases. Exposure of rats, rabbits, pigs and nonhuman primates to fumonisin-contaminated feed elevates sphingoid base amounts in urine; therefore, this study examined the time course and reversibility of these changes. When an AIN-76 diet supplemented with >/=5 microg FB1/g was fed to male Sprague-Dawley rats, there was a significant increase in sphinganine (ca. 50-fold in urine from rats fed 50 microg FB1/g diet) and smaller changes in sphingosine within 5 to 7 d, compared to rats fed the same diet without FB1. No change occurred in sphingoid bases upon feeding 1 microg FB1/g for up to 60 d. When rats were fed FB1 (10 microg FB1/g diet for 10 d), then changed to the same diet minus FB1, urinary sphingoid bases returned to normal within 10 d. However, if the rats were fed 10 microg FB1/g for 10 d, then changed to 1 microg FB1/g, the amounts of sphingoid bases in urine were the same as for rats that were continuously fed 10 microg FB1/g. These results establish that consumption of FB1 causes dose-dependent and reversible elevations in the amounts of urinary sphingoid bases. The finding that 1 microg FB1/g (which does not, alone, alter urinary sphingoid bases) will sustain the elevation caused by previous exposure to 10 microg FB1/g raises the possibility that even low levels of fumonisins could be deleterious when an animal is occasionally exposed to higher amounts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915902     DOI: 10.1093/jn/129.1.214

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  7 in total

Review 1.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

2.  Validation of fumonisin biomarkers in F344 rats.

Authors:  Qingsong Cai; Lili Tang; Jia-Sheng Wang
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-16       Impact factor: 4.219

Review 3.  Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins.

Authors:  A H Merrill; M C Sullards; E Wang; K A Voss; R T Riley
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

4.  Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border.

Authors:  Stacey A Missmer; Lucina Suarez; Marilyn Felkner; Elaine Wang; Alfred H Merrill; Kenneth J Rothman; Katherine A Hendricks
Journal:  Environ Health Perspect       Date:  2006-02       Impact factor: 9.031

Review 5.  Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis.

Authors:  R T Riley; E Enongene; K A Voss; W P Norred; F I Meredith; R P Sharma; J Spitsbergen; D E Williams; D B Carlson; A H Merrill
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

6.  Maternal mycotoxin exposure and adverse pregnancy outcomes: a systematic review.

Authors:  Nicholas N A Kyei; Daniel Boakye; Sabine Gabrysch
Journal:  Mycotoxin Res       Date:  2020-01-27       Impact factor: 3.833

7.  Evaluation of sphingolipids in Wistar rats treated to prolonged and single oral doses of fumonisin b₁.

Authors:  Glória M Direito; Adriana P Almeida; Simone Aquino; Tatiana Alves Dos Reis; Claudia Rodrigues Pozzi; Benedito Corrêa
Journal:  Int J Mol Sci       Date:  2008-12-27       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.